Cargando…

HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART

Patients with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) are at increased risk for developing Hodgkin's lymphoma (HL), a risk that has not decreased despite the success of combination antiretroviral therapy (cART) in the modern era. HIV-associated HL (HIV-HL) di...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobson, Caron A., Abramson, Jeremy S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3261478/
https://www.ncbi.nlm.nih.gov/pubmed/22272202
http://dx.doi.org/10.1155/2012/507257
_version_ 1782221600205045760
author Jacobson, Caron A.
Abramson, Jeremy S.
author_facet Jacobson, Caron A.
Abramson, Jeremy S.
author_sort Jacobson, Caron A.
collection PubMed
description Patients with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) are at increased risk for developing Hodgkin's lymphoma (HL), a risk that has not decreased despite the success of combination antiretroviral therapy (cART) in the modern era. HIV-associated HL (HIV-HL) differs from HL in non-HIV-infected patients in that it is nearly always associated with Epstein-Barr virus (EBV) and more often presents with high-risk features of advanced disease, systemic “B” symptoms, and extranodal involvement. Before the introduction of cART, patients with HIV-HL had lower response rates and worse outcomes than non-HIV-infected HL patients treated with conventional chemotherapy. The introduction of cART, however, has allowed for the delivery of full-dose and dose-intensive chemotherapy regimens with improved outcomes that approach those seen in non-HIV infected patients. Despite these significant advances, HIV-HL patients remain at increased risk for treatment-related toxicities and drug-drug interactions which require careful attention and supportive care to insure the safe administration of therapy. This paper will address the modern diagnosis, risk stratification, and therapy of HIV-associated HL.
format Online
Article
Text
id pubmed-3261478
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-32614782012-01-23 HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART Jacobson, Caron A. Abramson, Jeremy S. Adv Hematol Review Article Patients with human immunodeficiency virus/acquired immune deficiency syndrome (HIV/AIDS) are at increased risk for developing Hodgkin's lymphoma (HL), a risk that has not decreased despite the success of combination antiretroviral therapy (cART) in the modern era. HIV-associated HL (HIV-HL) differs from HL in non-HIV-infected patients in that it is nearly always associated with Epstein-Barr virus (EBV) and more often presents with high-risk features of advanced disease, systemic “B” symptoms, and extranodal involvement. Before the introduction of cART, patients with HIV-HL had lower response rates and worse outcomes than non-HIV-infected HL patients treated with conventional chemotherapy. The introduction of cART, however, has allowed for the delivery of full-dose and dose-intensive chemotherapy regimens with improved outcomes that approach those seen in non-HIV infected patients. Despite these significant advances, HIV-HL patients remain at increased risk for treatment-related toxicities and drug-drug interactions which require careful attention and supportive care to insure the safe administration of therapy. This paper will address the modern diagnosis, risk stratification, and therapy of HIV-associated HL. Hindawi Publishing Corporation 2012 2012-01-05 /pmc/articles/PMC3261478/ /pubmed/22272202 http://dx.doi.org/10.1155/2012/507257 Text en Copyright © 2012 C. A. Jacobson and J. S. Abramson. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Jacobson, Caron A.
Abramson, Jeremy S.
HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART
title HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART
title_full HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART
title_fullStr HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART
title_full_unstemmed HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART
title_short HIV-Associated Hodgkin's Lymphoma: Prognosis and Therapy in the Era of cART
title_sort hiv-associated hodgkin's lymphoma: prognosis and therapy in the era of cart
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3261478/
https://www.ncbi.nlm.nih.gov/pubmed/22272202
http://dx.doi.org/10.1155/2012/507257
work_keys_str_mv AT jacobsoncarona hivassociatedhodgkinslymphomaprognosisandtherapyintheeraofcart
AT abramsonjeremys hivassociatedhodgkinslymphomaprognosisandtherapyintheeraofcart